Viewing Study NCT02346032


Ignite Creation Date: 2025-12-24 @ 9:33 PM
Ignite Modification Date: 2026-03-29 @ 3:41 AM
Study NCT ID: NCT02346032
Status: COMPLETED
Last Update Posted: 2017-04-26
First Post: 2014-11-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Sponsor: Samsung Medical Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module